Breaking News Headlines Today | Ground News

See every side of every news story

pharmatimes.com image

News from pharmatimes.com

Your destination for news from pharmatimes.com. See how pharmatimes.com’s media bias impacts the breaking news stories of today.

We’ve discovered 67 headlines written by pharmatimes.com during the past 3 months.

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

Actithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...

Actithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...

100% Center coverage: 5 sources

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube...See the Story

Merck's SpringWorks Takeover Delivers a Drug Approval

Merck's SpringWorks Takeover Delivers a Drug Approval

100% Center coverage: 1 sources

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.See the Story

New Cystic Fibrosis Triple From Vertex Backed for NHS Use

New Cystic Fibrosis Triple From Vertex Backed for NHS Use

100% Center coverage: 1 sources

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.See the Story

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trialsProceeds will also help scale strategic partnerships…European Union See the Story

First Patient Dosed in Phase 2b Study of GlyphAllo for Patients With Major Depressive Disorder, With or Without Anxious Stress

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.Boston, Massachusetts · Boston See the Story

North East NHS Launches Digital Platform to Tackle Chronic Kidney Disease – RamaOnHealthcare

Healthinote rollout aims to improve early detection and patient self-managementNorth East and North Cumbria NHS has begun a year-long rollout of theUnited Kingdom · United Kingdom See the Story

Proximie Partners with HistoSonics to Boost Non-Invasive Liver Tumor Treatment

100% Center coverage: 1 sources

Proximie and HistoSonics collaborate to enhance non-invasive liver tumor treatments, improving patient outcomes and surgical efficiency through advanced technology integration.See the Story

Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer

New treatment targets BRAFV600E-mutant mCRC after prior therapyCancer · China Read Article

Imperial study reveals DNA structure that could reverse ovarian cancer resistance

Targeting G-quadruplexes may restore chemotherapy effectivenessHealthcare Read Article

MHRA Approves First Oral Treatment for Hereditary Angioedema Attacks

Sebetralstat offers injection-free relief for patients aged 12 and overUnited States · United States See the Story

GSK Begins Shipping Influenza Vaccine Doses for the 2025-26 Flu Season

100% Left coverage: 1 sources

PHILADELPHIA--(BUSINESS WIRE)--Jul 10, 2025-Flu Season · Philadelphia See the Story

Breaking News Topics Related to pharmatimes.com